X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BXCL701 (talabostat mesylate) is an investigational, oral small molecule inhibitor of a class of enzymes called DPPs, specifically DPP8/9 and DPP4. It is being evaluated for treatment of small cell neuroendocrine prostate cancer.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator. It is being evaluated in phase 2 clinial trials in combination with Keytruda (pembrolizumab) for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. it is currently being developed for combination with (pembrolizumab) in patients with mCRPC of Adenocarcinoma Phenotype.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2023
Details:
BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. it is currently being developed for combination with (pembrolizumab) in patients with small cell neuroendocrine prostate cancer.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. BXCL701 is currently being developed for aggressive forms of prostate cancer and advanced solid tumors.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. BXCL701 is currently being developed for aggressive forms of prostate cancer and advanced solid tumors.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
BXCL701 is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. BXCL701 is currently being developed as a potential therapy for the treatment of aggressive forms of prostate cancer and advanced solid tumors.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in tumor microenvironment, is being evaluated in combination with KEYTRUDA in an ongoing Phase 2 trial in mCRPC patients with either adenocarcinoma or SCNC phenotype.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
BXCL701 (talabostat mesylate), investigational orally administered innate immune activator plus KEYTRUDA (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma. BXCL701 is orally administered innate immune activator designed to initiate inflammation in tumor microenvironment.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Abstract titled "BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC)" will be presented at the conference.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The Phase 1b/2 trial is an open-label, multicenter study to evaluate the safety and efficacy of BXCL701 administered orally and daily, combined with pembrolizumab (KEYTRUDA®), in men with tNEPC.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
